Anion binding and controlled aggregation of human interleukin-1 receptor antagonist.
Highly concentrated human recombinant interleukin-1 receptor antagonist (IL-1ra) aggregates at elevated temperature without perturbation in its secondary structure. The protein aggregation can be suppressed depending on the buffer ionic strength and the type of anion present in the sample solution. Phosphate is an approximately 4-fold weaker suppressant than either citrate or pyrophosphate on the basis of the measured protein aggregation rates. This is in agreement with the strength of protein-anion interactions at the IL-1ra single anion-binding site as judged by the estimated dissociation constant values of 2.9 mM, 3.8 mM, and 13.7 mM for pyrophosphate, citrate, and phosphate, respectively. The strength of binding also correlates with the anion size and with the number of ionized groups available per molecule at a given pH. Affinity probing of IL-1ra with methyl acetyl phosphate (MAP) in combination with proteolytic digestion and mass spectral analysis show that an anion-binding site location on the IL-1ra surface is contributed by lysine-93 and lysine-96 of the loop 84-98 as well as by lysine-6 of the unstructured N-terminal region 1-7. The replacement of lysine-93 with alanine by site-directed mutagenesis results in dramatically suppressed IL-1ra aggregation. Furthermore, when the unstructured N-terminal region of IL-1ra is removed by limited proteolysis, a 2-fold increase in the time course of the aggregation lag phase is observed for the truncated protein. An anion-controlled mechanism of IL-1ra aggregation is proposed by which the anion competition for the protein cationic site prevents formation of intermolecular cation-pi interactions and, thus, interferes with the protein asymmetric self-association pathway.
Raibekas
Andrei A
AA
Department of Pharmaceutics, Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320, USA. andreir@amgen.com
Bures
Edward J
EJ
Siska
Christine C
CC
Kohno
Tadahiko
T
Latypov
Ramil F
RF
Kerwin
Bruce A
BA
D000345:Affinity Labels / Q000378:metabolism; D000838:Anions / Q000378:metabolism; D001665:Binding Sites / Q000235:genetics; D001667:Binding, Competitive / Q000235:genetics; D002412:Cations / Q000378:metabolism; D019343:Citric Acid / Q000378:metabolism; D011756:Diphosphates / Q000378:metabolism; D006358:Hot Temperature; D006801:Humans; D053590:Interleukin 1 Receptor Antagonist Protein; D008239:Lysine / Q000235:genetics; D016297:Mutagenesis, Site-Directed; D010710:Phosphates / Q000378:metabolism; D010746:Phosphonoacetic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D011489:Protein Denaturation; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D017384:Sequence Deletion; D012795:Sialoglycoproteins / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000235:genetics; D013329:Structure-Activity Relationship
D000345:Affinity Labels; D000838:Anions; D002412:Cations; D011756:Diphosphates; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D010710:Phosphates; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D019343:Citric Acid; C014660:methylacetylphosphonate; D008239:Lysine; D010746:Phosphonoacetic Acid